
Ocular Therapeutix, Inc.: stock overview
Price
$6.21
November 13, 2026Market cap $1.4B
What Ploutos Investor adds for Ocular Therapeutix
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
Ocular Therapeutix had revenue of $50M over the last 12 months and a net loss of $327M. Revenue grew by 24.5% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $1.4B
- 218M shares
- P/E
- –
- Revenue, 12 months
- $50M
- +24.5% a year over 5 years
- Net margin
- -648.6%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-5.7% a year over 2 years
Fiscal years in figures
OCUL's revenue, profit, cash flow and dividend with each year-end price, from 2012 to 2022, 10 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $1.4B
- $1.4B
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 4.3
- 3.1
- FCF yield 3-year median: -10.0%
- –
- Earnings yield 3-year median: -14.3%
- –
Profitability
- Gross margin
- 87.3%
- Operating margin
- -680.9%
- Net margin 3-year median: -303.7%
- -648.6%
- ROIC
- -48.1%
- ROIC, 5-year average
- -52.7%
- ROE
- -66.6%
Growth
- Revenue, yearly change
- -18.5%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +24.5%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $531M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -30.6x
- Current ratio
- 9.12
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +36.9%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
ROE
-40.6%
Above 20% of the 267 companies in its industry, and 8% of all.
ROA
-32.9%
Above 16% of the 313 companies in its industry, and 5% of all.
Revenue growth
-18.5%
Above 9% of the 292 companies in its industry, and 5% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- OCULAR THERAPEUTIX, INC
- CIK
- 1393434
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 218M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with OCUL
- JNJJohnson & Johnson+0,00%Compare with OCUL
- ABBVAbbVie+0,00%Compare with OCUL
- UNHUnitedHealth+0,00%Compare with OCUL
- MRKMerck & Company+0,00%Compare with OCUL
- AMGNAmgen+0,00%Compare with OCUL
- TMOThermo Fisher Scientific+0,00%Compare with OCUL
- ABTAbbott Laboratories+0,00%Compare with OCUL
The full analysis
What do Ocular Therapeutix's filings show?
These are Ocular Therapeutix's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is OCUL's market cap?
Ocular Therapeutix, Inc.'s market cap is $1.4B, at a price of $6.21 on November 13, 2026 and 218M shares.
How much revenue does OCUL have?
Ocular Therapeutix had revenue of $50M over the last 12 months. Over the last 5 years it changed by +24.5% a year on average.
Does OCUL pay a dividend?
No. Ocular Therapeutix paid no regular dividend over the last 12 months.
Where do the figures come from?
From Ocular Therapeutix, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.